oncopeptides

YEAR END REPORT, Q4 2025

Net sales more than doubled in 2025 with 125 percent growth, as glioblastoma program marks strategic pipeline expansion beyond multiple myeloma

Significant events

OCTOBER-DECEMBER

- Journal of Cancer Research and Clinical Oncology: Exceptional long-term responses to Pepaxti.
- Research by top universities together with Oncopeptides on NK cell engagers was presented at ASH.
- Annals of Hematology: Expert consensus supports use of Pepaxti in myeloma.
- Experimental Hematology & Oncology: Research shows that Pepaxti is effective in high-risk myeloma.

Financial overview

OCTOBER-DECEMBER

- **Net sales** amounted to SEK 18.6 (9.9) million
- **Operating profit** amounted to SEK -61.5 (-83.3) million
- **Profit after tax** amounted to SEK -65.2 (-83.4) million
- **Earnings per share**, before and after dilution -0.25 (-0.39) SEK
- **Cash and cash equivalents** at the end of the period amounted to SEK 82.3 (178.5) million

Events after the period

- Oncopeptides announces Q4 2025 sales and updates cash-flow expectations.
- Oncopeptides announces rights issue.

Selected Key Indicators

(SEK thousand)	2025 okt-dec	2024 okt-dec	2025 jan-dec	2024 jan-dec
Net sales	18 567	9 914	71 118	31 648
Operating profit	-61 530	-83 334	-224 651	-283 498
Profit after tax	-65 173	-83 426	-249 585	-284 607
Earnings per share before and after dilution (SEK)	-0,25	-0,39	-1,10	-1,71
Cash flow from operating activities	-60 064	-71 498	-216 493	-260 570
Cash at the end of the period	82 255	178 536	82 255	178 536

CEO Statement

Oncopeptides delivered strong commercial progress in 2025, with full-year net sales more than doubling to SEK 71.1 million, representing a 125 percent increase compared to 2024. For the fourth quarter, net sales reached SEK 18.6 million, an 88 percent increase year over year. This performance reflects a healthy demand for Pepaxti, particularly in Italy where the launch has exceeded our initial expectations. Going into 2026, our Peptide-Drug Conjugate (PDC) platform pipeline assets will progress beyond multiple myeloma into other diseases, potentially enabling significant future potential.

The successful yet complex market access processes in Spain and Italy were achieved ahead of schedule, requiring significant investments earlier than originally assumed to ensure proper team build-up. While our growth trajectory in Europe overall remains robust year-over-year, sales during the second half of the year were muted by a slower-than-expected uptake in Germany and a medical doctors' strike in Spain during Q4. Consequently, we have adjusted our expectations and now anticipate reaching positive cash flow in 2027.

To support this ambition, we have completed a strategic review of our German operations to sharpen focus and optimize our business model. By streamlining the organization focusing on high-potential areas, we aim to reach country-level profitability in Germany during 2026.

As previously communicated, negotiations for the Japanese market have recently focused in on one well-established, sizable pharmaceutical company, and we have recently progressed into formal contracting discussions. As the timeline is dependent on external factors out of our control, it is difficult to estimate when a deal can be closed.

We have seen exciting data further supporting the validation of our PDC platform, which allows us to target new, high-value indications with high unmet medical need, most notably Glioblastoma, a disease with no cure or new medical treatment options changing the prognosis and an estimated USD 8 billion global market. Leveraging the PDC platform's demonstrated ability to cross the blood-brain barrier in animal models, we are as a next step advancing a capital-efficient "Window of Opportunity" study to confirm our findings in humans. The study design has already received strong interest and support from several leading KOLs in Europe and the U.S. The study, targeted to start in 2026, will generate human proof-of-concept data of a PDC passing the blood-brain barrier in human.

If we are able to prove this, we have addressed one of the greatest challenges with drug development for this aggressive and severe brain tumor, opening up one of several exciting ways forward for the future development of our pipeline assets beyond multiple myeloma.

In order to facilitate this strategic shift from pre-clinical research into clinical development in glioblastoma and other indications, we are reallocating resources from pre-clinical internal research to clinical research. To stay cost-conscious and focused we are reducing our internal R&D efforts and will in the future rely more on external strategic collaborations to advance our two platforms PDC and SPiKE.

To bolster the company´s financial position, give further room for the ongoing commercialization of Pepaxti in Europe as well as to bring the company´s preclinical program in glioblastoma to clinical development, we have today announced a rights issue of up to SEK 200 million support from our largest shareholder HealthCap.

With more than 600 patients treated since our EMA approval and a clear inclusion in the EHA/EMN guidelines, Pepaxti is increasingly recognized as a viable treatment option for triple-class refractory patients. We enter 2026 with a more focused organization, a clear roadmap for geographic expansion and, not least, exciting pipeline advancement that can take the company from a niche player to a pioneer within several new indications, beyond late-stage myeloma. Our mission remains unchanged: bringing hope through science to patients with difficult-to-treat cancers. I believe that 2026 will be a year of significant progress for Oncopeptides.

Stockholm, February 19, 2026

Sofia Heigis
CEO

Financial Overview

REVENUE
Net sales of Pepaxti during the quarter were SEK 18.6 (9.9) million and for the full year SEK 71.1 (31.6) million. The turnover for the period refers to Europe only, whereas last year SEK 1.1 million related to a milestone payment in Korea.

GROSS PROFIT
Gross profit during the quarter were SEK 16.7 (9.2) million and for the full year SEK 68.7 (29.0) million. In the fourth quarter a one-time inventory write-down of SEK 1.7 million was recorded, affecting cost of goods sold.

OPERATING EXPENSES
Operating expenses during the quarter were SEK 78.2 (92.5) million and for the full year SEK 293.3 (312.5) million.

RESEARCH AND DEVELOPMENT EXPENSES
Research and development costs during the quarter were SEK 25.2 (43.2) million and for the full year SEK 103.0 (121.2) million. No clinical studies are currently ongoing.

MARKETING AND SALES EXPENSES
Marketing and sales costs during the quarter were SEK 40.2 (42.7) million and for the full year SEK 137.2 (136.4) million. The costs relate to ongoing commercialization activities in Europe, focusing on Germany, Spain and Italy.

GENERAL AND ADMINISTRATIVE EXPENSES
Administrative costs during the quarter were SEK 13.7 (8.1) million and for the full year SEK 57.4 (60.8) million. The company implemented cost reductions during the fourth quarter 2024, explaining the difference versus the fourth quarter 2025. Total cost for 2025 is still below corresponding cost for 2024.

EXPENSES FOR SHARE BASED INCENTIVE PROGRAMS
For the full year, costs, including social security contributions, for share-related incentive programs amounted to SEK 5.6 (9.0) million. The cost does not affect cash flow in the period. See note 8.

TAX AND EARNINGS
Profit during the quarter were SEK -65.2 (-83.4) million and for the full year SEK -249.6 (-284.6) million. This corresponds to earnings per share for the quarter of SEK -0.25 (-0.39) and for the full year SEK -1.10 (-1.71). Profit affected by a non-cash fair valuation effect of warrants related to the EIB-loan (see note 6) of SEK -12.2 (4.7) million.

CASH FLOW, INVESTMENTS AND FINANCIAL POSITION
Cash flow from operating activities for the full year amounted to SEK -216.5 (-260.6) million.

In September the company conducted a rights issue fueling liquidity with SEK 133 million and repaid a credit facility of SEK 20 million that was drawn during the second quarter.

Equity in the group amounted to SEK -58.9 (54.3) million at the end of the period. Equity for the parent company amounted to SEK 386.2 (527.5) million.

GOING CONCERN
As per announced rights issue described below the financial statements have been prepared on the assumption that the company has the ability to continue operations for the coming 12-month period, in line with the going concern principle.

RIGHTS ISSUE 2026
On February 19, the company announced that the board of directors has decided to carry out a guaranteed new share issue of approximately MSEK 200 (guaranteed up to MSEK 190 including subscription commitments from the company's largest owner and its board and management) with preferential rights for the company's existing ordinary shareholders based on the authorization from the annual general meeting on May 22, 2025, with the support of the company's largest shareholder and management. The purpose of the rights issue is primarily to finance the ongoing commercialization of Pepaxti® in Europe until the commercial part of the company expects to have a positive cash flow in 2027, as well as a targeted development of the company's project for the indication Glioblastoma into clinical phase.

RIGHTS ISSUE 2025
The Rights Issue encompassed 46,947,534 new ordinary shares, of which 43,862,586 ordinary shares, corresponding to approximately 93 percent of the offered ordinary shares, were subscribed for by exercise of subscription rights. Additionally, applications for subscription of 29,834,852 ordinary shares without subscription rights were submitted, corresponding to approximately 64 percent of the offered ordinary shares. Thus, the Rights Issue is fully subscribed injecting the company with some SEK 150 million before issue related cost. The subscription price was SEK 3.20 per new ordinary share. Through the Rights Issue, the share capital was increased by SEK 5,216,392.88, from SEK 25,084,314.69 to SEK 30,300,707.56, by a new issue of 46,947,534 new ordinary shares, resulting in the total number of shares increasing from 225,758,823 shares to 272,706,357 shares (including C-shares) The number of ordinary shares will increase from 211,269,903 ordinary shares to 258,211,437 ordinary shares.

EMPLOYEES
At the end of the quarter, the number of employees amounted to 75 (80).

PARENT COMPANY
The operations of the parent company correspond in all essential respects with the operations of the group, which is why the comments for the group also apply to the parent company.

ONCOPEPTIDES SHARE
At the end of the period, the number of registered shares eligible for trading and votes in Oncopeptides amounted to 272,706,357, inclusive of 14,138,885 C-shares held by the company.

DIVIDEND
In accordance with the adopted dividend policy no dividend is suggested for fiscal year 2025.

AUDITOR REVIEW
This report has not been reviewed by the company's auditors.

Signatures

The Board and the CEO confirm that the interim report provides a true and fair reflection of the Group's and the Parent Company's operations, position and earnings and describes the material risks and uncertainty factors faced by the Parent Company and the companies within the Group.

Stockholm, February 19, 2025

Per Wold-Olsen
Chairman

Sofia Heigis
CEO

Christine Rankin
Board member

Per Samuelsson
Board member

Brian Stuglik
Board member

Condensed consolidated statement of comprehensive income

(SEK thousand)	Note	2025 okt-dec	2024 okt-dec	2025 jan-dec	2024 jan-dec
Net sales	5	18 567	9 914	71 118	31 648
Cost of Goods Sold		-1 853	-727	-2 451	-2 663
Gross profit		**16 714**	**9 187**	**68 667**	**28 985**
Research and development expenses		-25 243	-43 150	-102 970	-121 186
Marketing and distribution expenses		-40 171	-42 709	-137 183	-136 439
Administrative expenses		-13 678	-8 102	-57 439	-60 843
Other operating income/expenses		849	1 440	4 274	5 985
Total operating expense		**-78 244**	**-92 521**	**-293 318**	**-312 483**
EBIT; Operating profit/loss		**-61 530**	**-83 334**	**-224 651**	**-283 498**
Net financial items		-2 461	697	-23 519	-712
EBT; Earnings before taxes		**-63 991**	**-82 637**	**-248 169**	**-284 209**
Income tax		-1 182	-789	-1 415	-398
Net profit		**-65 173**	**-83 426**	**-249 585**	**-284 607**
Other comprehensive income					
Items to be reclassified as profit or loss					
Translation variances		-120	-467	-367	-644
Other comprehensive income after tax		**-120**	**-467**	**-367**	**-644**
Total comprehensive income attributable to Parent Company's shareholders.		**-65 293**	**-83 892**	**-249 952**	**-285 251**
Earnings per share before/after dilution (SEK)		**-0,25**	**-0,39**	**-1,10**	**-1,71**

Condensed consolidated statement of financial position

TSEK	Note	2025-12-31	2024-12-31
Assets			
Tangible assets		17 682	27 111
Financial assets		-	-
Total non-current assets		**17 682**	**27 111**
Current assets			
Inventory		8 244	4 371
Current receivables		26 660	34 174
Cash		82 255	178 536
Total current assets		**117 159**	**217 081**
Total assets		**134 841**	**244 192**
Equity and liabilities			
Equity		-58 891	54 285
Total equity		**-58 891**	**54 285**
Long term liabilities			
Loans from credit institutions	6	126 681	121 894
Other long term liabilities		22 547	16 658
Total long-term liabilities		**149 228**	**138 552**
Current liabilities			
Trade payables		701	18 171
Other curren liabilities		43 803	33 185
Total current liabilities		**44 504**	**51 355**
Total equity and liabilities		**134 841**	**244 192**

Condensed consolidated statement of changes in equity

SEK Thousand	2025 okt-dec	2024 okt-dec	2025 jan-dec	2024 jan-dec
Opening balance	**6 538**	**135 656**	**54 285**	**56 780**
Net profit	-65 173	-83 426	-249 585	-284 607
Other comprehensive income	-120	-467	-367	-644
Total comprehensive income	**-65 293**	**-83 892**	**-249 952**	**-285 251**
Transaction with owners				
New issue of shares	0	0	150 232	313 483
Cost related to share issue	0	0	-17 347	-41 639
Share based compensation	-137	2 522	3 890	10 913
Total transactions with owners	**-137**	**2 522**	**136 776**	**282 756**
Ending balance	**-58 891**	**54 285**	**-58 891**	**54 285**

Condensed consolidated statement of cash flow

SEK Thousand	2025 okt-dec	2024 okt-dec	2025 jan-dec	2024 jan-dec
Operating activities				
Operating profit/loss	-61 530	-83 334	-224 651	-283 498
Adjustment for non-cash items	-13 564	12 217	-13 770	18 620
Interest received	1 652	6 381	1 671	6 403
Interest paid	0	-4	0	-4
Taxes paid	106	337	-114	588
Cash-flow from operating activities before change in working capital	**-73 336**	**-64 403**	**-236 864**	**-257 891**
Change in working capital	13 272	-7 095	20 371	-2 679
Cash-flow from operating activities	**-60 064**	**-71 498**	**-216 493**	**-260 570**
Cash-flow from investment activities	-	496	0	496
Cash-flow from financing activities	-5 338	-2 060	122 163	263 814
Cash-flow for the period	**-65 402**	**-73 062**	**-94 330**	**3 740**
Cash at the beginning of the period	147 917	250 013	178 536	173 407
Change in cash	-65 403	-73 062	-94 331	3 740
Effect of exchange rate changes on cash	-259	1 585	-1 951	1 389
Cash at the end of the period	**82 255**	**178 536**	**82 255**	**178 536**

Condensed Parent Company income statement

(SEK thousand)	Note	2025 okt-dec	2024 okt-dec	2025 jan-dec	2024 jan-dec
Net sales	5	18 567	9 914	71 118	31 648
Cost of Goods Sold		-1 853	-727	-2 451	-2 663
Gross profit		**16 714**	**9 187**	**68 667**	**28 985**
Research and development expenses		-25 300	-45 426	-103 218	-125 954
Marketing and distribution expenses		-40 201	-44 383	-141 003	-140 279
Administrative expenses		-16 936	-8 115	-71 491	-60 983
Other operating income/expenses		1 595	5 943	10 890	520 564
Total operating expense		**-80 842**	**-91 981**	**-304 822**	**193 349**
EBIT; Operating profit/loss		**-64 128**	**-82 794**	**-236 155**	**222 334**
Net financial items		3 215	6 113	-255	5 898
Earnings after net financial items		**-60 914**	**-76 681**	**-236 410**	**228 232**
Group contribution		-2 043	-16 715	-41 591	-43 655
EBT; Earnings before taxes		**-62 956**	**-93 396**	**-278 001**	**184 577**
Tax		0	0	0	0
Net profit		**-62 956**	**-93 396**	**-278 001**	**184 577**

Condensed Parent Company statement of comprehensive income

SEK thousand	2025 okt-dec	2024 okt-dec	2025 jan-dec	2024 jan-dec
EBT; Earnings before taxes	-62 956	-93 396	-278 001	184 577
Other comprehensive income	-	-	-	-
Net profits	**-62 956**	**-93 396**	**-278 001**	**184 577**

Condensed Parent Company balance sheet

SEK thousand	Note	2025-12-31	2024-12-31
Assets			
Tangible assets		3 783	6 053
Financial assets		510 745	500 445
Total non-current assets		**514 528**	**506 498**
Current assets			
Inventory		8 244	4 371
Current receivables		97 400	108 220
Cash		74 859	141 143
Total current assets		**180 503**	**253 734**
Total assets		**695 031**	**760 233**
Equity and liabilities			
Restricted equity		40 509	34 118
Non-restricted capital		345 767	493 383
Total Equity		**386 277**	**527 502**
Long term liabilities			
Loans from credit institutions	6	126 198	121 894
Long-term liabilities		18 046	4 110
Total long-term liabilities		**144 245**	**126 004**
Current liabilities			
Trade payables		0	15 318
Other current liabilities		164 510	91 409
Total current liabilities		**164 510**	**106 727**
Total equity and liabilities		**695 031**	**760 233**

NOTE 1 - GENERAL INFORMATION

This year-end report covers the Swedish parent company Oncopeptides AB (publ), registration number 556596-6438, as well as the wholly owned subsidiaries Oncopeptides Incentive AB, Oncopeptides Innovation AB (with the wholly owned subsidiary Oncopeptides Innovation 1 AB), Oncopeptides GmbH and Oncopeptides Srl and Oncopeptides SL. The parent company is a public limited company based in Stockholm. The figures in brackets in the report refer to the corresponding period of the previous year. The interim report has been approved for publication on 19 February 2026.

NOTE 2 - ACCOUNTING PRINCIPLES

The group's year-end report is prepared in accordance with IAS 34. The parent company applies the Swedish Financial Reporting Council's recommendation RFR 2. Oncopeptides applies, other than what appears below, the same accounting principles as in the most recent annual report. Significant accounting and valuation principles can be found on pages 43-48 of the annual report for 2024. No new or changed standards have been introduced since 1 January 2025 that have had any significant impact on the company's financial reporting.

Oncopeptides applies ESMA's (European Securities and Markets Authority) guidelines for alternative key figures.

NOTE 3 - RISKS AND UNCERTAINTIES

In its operations, Oncopeptides is exposed to a number of risks. The company continuously evaluates known and predictable risks and acts to minimize the effect of these risks within the framework of the company's business strategy and safeguarding the company's long-term interests, including its sustainability. The company assesses that the risks described in the annual report for 2024 remain during the period.

NOTE 4 - ESTIMATES AND CONSIDERATIONS

This report contains forward-looking statements. Actual results may differ from those stated. Internal factors such as successful management of research programs and intellectual property rights may affect future results. The year-end report has been prepared with the assumption that the company has the ability to continue operations during the next 12-month period, in line with the going concern principle.

NOTE 5 - REVENUE RECOGNITION

There has been no change in the principle of revenue recognition compared to the annual report 2024. Revenue is recognized at the transaction price for goods sold excluding value added tax, but including discounts. Revenue is recognized at the time of delivery when Oncopeptides has fulfilled its performance commitment and control of the goods passes to the customer.

The customers are defined as hospitals and/or clinics and retailers who sell the goods to the final user of the goods. As the final price is related to the discount that applies in the respective local market the parent company and the group report a liability for a calculated discount based on the frameworks for discounts that apply in each market. The provision for estimated discounts is reported under the heading Other short-term liabilities in the balance sheet.

Group revenue	2025	2024	2025	2024
SEK thousand	okt-dec	okt-dec	jan-dec	jan-dec
Net sales				
Goods	18 567	9 914	71 118	30 517
Milestone South Korea	0	0	0	1 131
Total net revenue	**18 567**	**9 914**	**71 118**	**31 648**
Geographical market				
Europe	18 567	9 914	71 118	30 517
Asia	0	0	0	1 131
Total net revenue	**18 567**	**9 914**	**71 118**	**31 648**

NOTE 6 – LOANS FROM CREDIT INSTITUTIONS

The liability relate to a loan from EIB in EURO. It will not be amortized until the 16th of June 2028, when it will be fully repaid. The interest is accumulated and capitalized during the term and paid in connection to the repayment of the loan. The contractual interest rate is 7% for the full term. The effective interest rate is estimated to 10.8%, including arrangement costs and the initial market value of the transferred warrants allocated during the term of the loan.

In connection to the signing of the agreement, an issue of warrants was performed, whereof 3 383 326 warrants representing 1.26% of outstanding shares after dilution has been transferred to EIB without compensation. As of end year-end 2025 the company has no longer the ability draw additional tranches on the loan.

EIB has the right to exercise the warrants and subscribe for shares at the quota value. The warrants may be exercised at any time for a period of 20 years, in full or in part, by the warrant holder.

EIB has the right, under certain circumstances and in connection to the repayment of the loan, to demand that Oncopeptides acquire the warrants at fair value in a situation when it is not possible to transfer the warrants to a third party.

NOTE 7 - RELATED PARTY TRANSACTIONS

Remuneration to senior management has been paid in accordance with current policies. No other transactions with related parties, outside of the Oncopeptides Group, occurred during the period.

NOTE 8 - SHARE BASED INCENTIVE PROGRAMS

The purpose of share-based incentive programs is to promote the company's long-term interests by motivating and rewarding the company's senior management, founders, and other co-workers in line with the interest of the shareholders. Oncopeptides has currently nine programs that include the management team, certain Board members, founders and employees.

Program
- 2017; "Co-worker LTIP 2017"
- 2018; "Co-worker LTIP 2018"
- 2019; "Co-worker LTIP 2019"
- 2022; "Co-worker LTIP 2022" and "Board SHP 2022"
- 2023; "Board SHP 2023"
- 2024; " Co-worker LTIP 2024" and "Board SHP 2024"
- 2025; "Board SHP 2025"

For more information on the programs see Note 26 in the Annual report 2024 as well as Agendas and Minutes from the relevant Annual General Meetings on the company's website www.oncopeptides.com.

At the end of the period, full utilization (including warrants for securing social security contributions but excluding warrants related to EIB), of
- Options and share awards resolved by the AGM and awarded to named individuals corresponding to 9,207,639 shares, would result in a dilution of 3.4 percent.
- Options and share awards resolved by the AGM and awarded to named individuals as well as those not yet awarded to individuals, corresponding to 15,606,801 shares, would result in a dilution of 5.7 percent.

NOTE 9 - SIGNIFICANT EVENTS AFTER THE PERIOD

No significant events occurred after the end of the period other than as mentioned in the report.

Key performance measures

In this report, certain key performance measures are presented, including measures that are not defined under IFRS,

- Research and development / operating expenses, %,
- Gross margin, TSEK, %.

The company believes that these measurements provides valuable additional information when evaluating the company's economic trends. These financial performance measures should not be viewed in isolation, nor be considered in replacement of performance indicators that are prepared in accordance with IFRS.

Further, such performance measures, as the company has defined them, should not be compared with other performance measures with similar names used by other companies since definitions and calculation methods may vary between companies.

SEK, Thousand	2025 okt-dec	2024 okt-dec	2025 jan-dec	2024 jan-dec
Net sales	18 567	9 914	71 118	31 648
Gross profit[1]	16 714	9 187	68 667	28 985
Gross margin[2]	90%	93%	97%	92%
Registered common shares outstanding				
beginning of period	211 263 903	211 263 903	211 263 903	90 439 627
end of period	258 567 472	211 263 903	258 567 472	211 263 903
C-shares for LTI programs[3]	14 138 885	3 922 343	14 138 885	3 922 343
Registered shares; end of period including C-shares	272 706 357	215 186 246	272 706 357	215 186 246
Share capital at the end of period	30 301	23 910	30 301	23 910
Equity at the end of period	-58 891	54 285	-58 891	54 285
Earnings per share before/after dilution, kr[4]	-0,25	-0,39	-1,10	-1,71
Operating loss	-61 530	-83 334	-224 651	-283 498
Research and development expenses	-25 243	-43 150	-102 970	-121 186
R&D costs/operating expenses, %[5]	32%	47%	35%	39%

1) Defined by subtracting cost of goods sold from total sales. The key figure shows gross profitability of cost of goods sold in absolute numbers.
2) Defined by dividing the sum of the company's gross profit by total sales. The key figure aims to clarify the relative profitability of goods sold.
3) For more information, please see the notice to the Annual General Meeting 2025.
4) Earnings per share before dilution are calculated by dividing earnings attributable to shareholders of the Parent Company by a weighted average number of outstanding shares during the period. There is no dilution effect driven by the employee stock option program, as earnings for the periods have been negative.
5) Defined by dividing the research and development costs with total operating expenses. The key performance measure provides an indication of the proportion of expenses that are attributable to the company's core business.

Telephone conference

The year-end report for the period and an operational update will be presented by CEO Sofia Heigis and members of Oncopeptides Leadership team, Thursday February 19, 2025, at 09:00 (CET).

If you wish to participate via **webcast**, please use the link below. Through the webcast you can ask written questions.
https://oncopeptides.events.inderes.com/q4-report-2025

If you wish to participate via **telephone conference**, please register on the link below. After registration you will be provided a phone numbers and a conference ID to access the conference. You can ask questions verbally via the telephone conference.

https://conference.inderes.com/teleconference/?id=5005165

Financial Calendar

Report	Date
Annual report 2025	28 April 2026
Interim report Q1 2026	13 May 2026
Interim report Q2 2026	27 August 2026
Interim report Q3 2026	5 November 2026

Contact

Oncopeptides AB
Visiting address; Luntmakargatan 46, 111 37 Stockholm
Domicile: Luntmakargatan 46, 111 37 Stockholm, Sweden

Telephone: +46 8 615 20 40
E-mail: info@oncopeptides.com

Website: oncopeptides.com

Thesaurus

EMA	European Medicines Agency Europeiska läkemedelsmyndigheten
CHMP	The European Medicines Agency's Committee for Medicinal Products for Human Use Europeiska läkemedelsmyndighetens kommitté för humanläkemedel